BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31755214)

  • 1. Inhibition of cyclin-dependent kinase 7 down-regulates yes-associated protein expression in mesothelioma cells.
    Miao J; Kyoyama H; Liu L; Chan G; Wang Y; Urisman A; Yang YL; Liu S; Xu Z; Bin H; Li H; Jablons DM; You L
    J Cell Mol Med; 2020 Jan; 24(1):1087-1098. PubMed ID: 31755214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
    Hsu PC; Miao J; Wang YC; Zhang WQ; Yang YL; Wang CW; Yang CT; Huang Z; You J; Xu Z; Jablons DM; You L
    J Cell Mol Med; 2018 Jun; 22(6):3139-3148. PubMed ID: 29575535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting YAP in malignant pleural mesothelioma.
    Zhang WQ; Dai YY; Hsu PC; Wang H; Cheng L; Yang YL; Wang YC; Xu ZD; Liu S; Chan G; Hu B; Li H; Jablons DM; You L
    J Cell Mol Med; 2017 Nov; 21(11):2663-2676. PubMed ID: 28470935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
    Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
    J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
    J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
    Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
    J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDK7 regulates organ size and tumor growth by safeguarding the Hippo pathway effector Yki/Yap/Taz in the nucleus.
    Cho YS; Li S; Wang X; Zhu J; Zhuo S; Han Y; Yue T; Yang Y; Jiang J
    Genes Dev; 2020 Jan; 34(1-2):53-71. PubMed ID: 31857346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells.
    Horio M; Sato M; Takeyama Y; Elshazley M; Yamashita R; Hase T; Yoshida K; Usami N; Yokoi K; Sekido Y; Kondo M; Toyokuni S; Gazdar AF; Minna JD; Hasegawa Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3(Suppl 3):S634-45. PubMed ID: 22086445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma.
    Kato T; Lee D; Wu L; Patel P; Young AJ; Wada H; Hu HP; Ujiie H; Kaji M; Kano S; Matsuge S; Domen H; Kanno H; Hatanaka Y; Hatanaka KC; Kaga K; Matsui Y; Matsuno Y; De Perrot M; Yasufuku K
    Int J Oncol; 2016 Dec; 49(6):2411-2420. PubMed ID: 27840913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
    Maille E; Brosseau S; Hanoux V; Creveuil C; Danel C; Bergot E; Scherpereel A; Mazières J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Langlais A; Morin F; Levallet G; Zalcman G
    Br J Cancer; 2019 Feb; 120(4):387-397. PubMed ID: 30739911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial.
    Maille E; Levallet J; Dubois F; Antoine M; Danel C; Creveuil C; Mazieres J; Margery J; Greillier L; Gounant V; Moro-Sibilot D; Molinier O; Léna H; Monnet I; Bergot E; Langlais A; Morin F; Scherpereel A; Zalcman G; Levallet G
    Int J Cancer; 2022 Jun; 150(11):1889-1904. PubMed ID: 35262190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-occurring Mutations of Tumor Suppressor Genes,
    Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
    [No Abstract]   [Full Text] [Related]  

  • 14. Gli as a novel therapeutic target in malignant pleural mesothelioma.
    Li H; Lui N; Cheng T; Tseng HH; Yue D; Giroux-Leprieur E; Do HT; Sheng Q; Jin JQ; Luh TW; Jablons DM; He B
    PLoS One; 2013; 8(3):e57346. PubMed ID: 23483902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.
    Li T; Li H; Wang Y; Harvard C; Tan JL; Au A; Xu Z; Jablons DM; You L
    J Pathol; 2011 Mar; 223(4):519-30. PubMed ID: 21294125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma.
    Mogi A; Koga K; Aoki M; Hamasaki M; Uesugi N; Iwasaki A; Shirakusa T; Tamura K; Nabeshima K
    Virchows Arch; 2013 Jan; 462(1):83-93. PubMed ID: 23187830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CK2α, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells.
    Zhang S; Yang YL; Wang Y; You B; Dai Y; Chan G; Hsieh D; Kim IJ; Fang LT; Au A; Stoppler HJ; Xu Z; Jablons DM; You L
    J Exp Clin Cancer Res; 2014 Nov; 33(1):93. PubMed ID: 25422081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma.
    Wang H; Dai YY; Zhang WQ; Hsu PC; Yang YL; Wang YC; Chan G; Au A; Xu ZD; Jiang SJ; Wang W; Jablons DM; You L
    Int J Oncol; 2017 Jul; 51(1):91-103. PubMed ID: 28560410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells.
    Hoda MA; Münzker J; Ghanim B; Schelch K; Klikovits T; Laszlo V; Sahin E; Bedeir A; Lackner A; Dome B; Setinek U; Filipits M; Eisenbauer M; Kenessey I; Török S; Garay T; Hegedus B; Catania A; Taghavi S; Klepetko W; Berger W; Grusch M
    Br J Cancer; 2012 Dec; 107(12):1978-86. PubMed ID: 23169291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
    Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS
    Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.